Contact this trialFirst, we need to learn more about you.
Checkpoint Inhibitor
Atezolizumab + CYT107 for Bladder Cancer
Recruiting1 awardPhase 2
Saint Louis, Missouri
This trial studies atezolizumab given with glycosylated recombinant human interleukin-7 to see how well it works in treating patients with urothelial carcinoma.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.